He stated in the abstract that there were no significant differences between arms of the study. If the control arm was sicker than they were in the historical data, so were the treatment arms.
What will matter to the FDA, given all arms are equal, is the relative differences between the arms of this study.
The trial only controlled the variables of this trial, not all past clinical trials.
Market Data 
Markets 
AI
